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TO DOPAMINE AND BEYOND, A REVIEW OF THE MECHANISMS OF 
PARKINSON’S DISEASE  
ANDREW E. CHESTER  
ABSTRACT 
Parkinson’s Disease is a disorder of the midbrain dopaminergic system with 
characteristic neurodegenerative patterns, recognized for its motor symptoms. The 
neurodegeneration is most prevalent in the substantia nigra pars compacta, while 
dopaminergic neurons in neighboring structures are comparatively spared. There are 
many possible explanations for this disparity, including differences in tolerance to 
oxidative stress, and vulnerability to α-synuclein aggregates. The substantia nigra is part 
of the basal ganglia, a network of nuclei in the midbrain and base of the forebrain which 
are responsible for coordinating voluntary movement. Dopamine has an inhibitory effect 
in the basal ganglia. It dampens signals to remove noise, so the basal ganglia circuitry is 
not hyperactive. In the absence of dopamine, the flow of information through the basal 
ganglia is disrupted. This results in tremor, bradykinesia, and rigidity, known as the 
classic triad. No cure currently exists and therapies are unable to slow disease 
progression, so treatments are aimed at symptom management. Degenerative processes in 
Parkinson’s Disease occur rapidly, early in the disease progression, with about 60% 
neuronal death in the substantia nigra prior to diagnosis. There is a need for biomarkers 
or other signs which can be used to clinically to diagnose the disease at an earlier stage. 
In conclusion this paper provides suggestions for future lines of research.   
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INTRODUCTION 
Parkinson’s Disease in its modern conception has a history dating back over 200 years. 
Dr. James Parkinson first formally described the condition in 1817, attributing the name 
‘shaking palsy’, or paralysis agitans, to the set of signs and symptoms to which we have 
now affixed the Physician’s eponym (Parkinson, 2002). In his initial paper, Dr. Parkinson 
referred to the palsy as “involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to bend the trunk 
forwards, and to pass from a walking to a running pace: the senses and intellects being 
uninjured” (Parkinson, 2002, p. 223). Indeed, the description by Dr. Parkinson alludes to 
the now-standard set of symptoms which are used clinically to diagnose Parkinson’s 
Disease (PD). That set, often referred to as the ‘classic’ triad, is composed of baseline 
tremor, rigidity, and bradykinesia (DeMaagd & Philip, 2015).  
The tremor is present in 70-90% of patients and is generally around 4-6Hz when 
resting. The rigidity in PD is present in 80-90% of patients, and is often described as 
‘cogwheel’ rigidity. This pattern resists passive movement for a short time until tension is 
released and the motion clicks into the next position, where tension builds again as if it 
were guided by a halting cogwheel. Bradykinesia, also present in 80-90% of patients, is 
notable for slowness of movement and in some cases movement ceases entirely, a 
phenomenon known as akinesia. A fourth notable symptom of the disease is postural 
instability, which is not considered part of the classic triad but still has diagnostic 
relevance. Collectively these motor abnormalities are referred to as parkinsonism 
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(DeMaagd & Philip, 2015). PD, particularly in its later stages, is also associated with 
cognitive symptoms including dementia, delayed reaction times, and difficulty 
coordinating motor sequences (Breen & Lang, 2017; Helie et al., 2013). 
In most basic terms, PD is a disorder of the extrapyramidal system, in that it 
involves tracts of the motor cortex that are not a component of the medullary pyramids 
(DeMaagd & Philip, 2015). It involves a wide range of neural structures in the midbrain 
and forebrain, and it has been shown that dopamine is a neurotransmitter playing a major 
role in the modulation of neurons in the basal ganglia. The connection between dopamine 
and disease progression in PD dates back to the mid-twentieth century, however, the 
exact role of dopamine and the pathophysiology of PD is still debated (Vogt Weisenhorn 
et al., 2016). Several researchers have found that parkinsonism motor symptoms present 
clinically once about 60% of the dopaminergic neurons in the substantia nigra have 
degenerated (DeMaagd & Philip, 2015; Vogt Weisenhorn et al., 2016). Given the 
magnitude of this loss before clinically significant signs of disease appear, there is an 
obvious need to discover new methods for early detection (Breen & Lang, 2017; 
DeMaagd & Philip, 2015). 
 There are not yet any tests to directly confirm Parkinson’s Disease, so a diagnosis 
is made clinically by confirming presence of parkinsonism features and then ruling out 
any other disease which has a similar presentation. Care must be taken to examine for 
other similar diseases and comorbidities, as many of these conditions have vastly 
different pathophysiology and would not respond to treatment geared towards 
Parkinson’s Disease (DeMaagd & Philip, 2015). There are several cases where 
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parkinsonism is caused by conditions with a more favorable prognosis, such as drug-
induced parkinsonism, and these can easily be treated by changing medications. This 
avoids burdening the patient with undue medical and social concerns. Other diseases 
which commonly  present with parkinsonism include Alzheimer’s disease, benign 
essential tremor, cerebrovascular disease, Lewy body dementia, Creutzfeldt-Jakob 
disease, and subdural hematoma, although this list is far from exhaustive (DeMaagd & 
Philip, 2015). 
 At present there is no cure for PD. Current treatments all are aimed at managing 
symptoms rather than slowing progression of degeneration (Mostile et al., 2017). 
Treatments involving dopamine replacement has been shown to effectively control the 
motor symptoms of the disease (Mostile et al., 2017), but these therapies do not stop 
underlying disease progression (Willis et al., 2012).  
 There are many reasons why we do not have a cure for Parkinson’s disease. Little 
is understood about the molecular nature of PD. Its genetic origins, the possibility of 
detectable biomarkers, and even the mechanism underlying dopaminergic degeneration 
remain uncertain (DeMaagd & Philip, 2015; Vogt Weisenhorn et al., 2016; Willis et al., 
2012).
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Neuroanatomy 
 
Figure 1 Coronal sections of Basal Ganglia. Source: Wikimedia Commons 
https://commons.wikimedia.org/wiki/File:Basal-ganglia-coronal-sections-large.png 
PD’s etiology is rooted in the degeneration of dopaminergic neurons in the SNc, 
so this is a good structure with which to begin an explanation of the relevant 
neuroanatomy and neurophysiology. The SN is a BG structure located in the ventral 
mesencephalon. First described by Felix Vicq d’Azyr in 1784, the SNc is visibly darker 
than the surrounding material when observed in autopsy, thus earning its Latin name 
which translates to ‘black substance’ (Tubbs et al., 2011). The dark color results from 
high concentrations of neuromelanin, which is related to the dopamine synthesis 
pathway. Increased levels of neuromelanin indicate an increased presence of dopamine, 
and likewise low neuromelanin indicates low dopamine levels (Rabey & Hefti, 1990). 
There is evidence to suggest that neuromelanin concentration naturally increases with age 
(Tribl et al., 2009; Gibb & Lees, 1991), but in PD patients this neuromelanin is depleted 
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to the point that its absence is noticeable to the naked eye (Vogt Weisenhorn et al., 2016). 
About 60% of dopaminergic neurons in the SNc are depleted by the time parkinsonian 
motor signs are first clinically reported (DeMaagd & Philip, 2015).  
There is a widely-accepted categorization method used to describe cell 
populations in the brain outlined by Dahlström and Fuxe (1964), which differentiated 
groups of brainstem cells from the medulla to the thalamus per their catecholaminergic 
behavior. In total there were 17 cell groups labeled A1-A17, of which nine groups are 
dopaminergic. The other groups are adrenergic or noradrenergic. A8-A16 are the 
dopaminergic groups, with A8-A10 in the ventral mesencephalon. A-9 is roughly aligned 
with the SN, mostly in SNc but some lesser presence in SNr, and A-10 matches up well 
with the ventral tegmental area (Dahlstroem & Fuxe, 1964).  
Collectively, the A8-A10 cell groups, the anatomical structures they map onto, 
and the other non-dopaminergic neurons in the region are often referred to as the ventral 
mesencephalic dopaminergic complex (Yetnikoff et al., 2014). This area has 20,000-
30,000 neurons in rodents, 160,000-320,000 neurons in monkeys, and 400,000-600,000 
neurons in human brains. Despite the increased complexity of the human ventral 
mesencephalon compared to rodents, animal models have been shown to effectively 
account for the complex disease progression of PD (Vogt Weisenhorn et al., 2016). Much 
of the complexity in primates is in the SN; rodent dopaminergic neurons are found in 
equal number in the SN and VTA, but in humans the SN dopaminergic neurons far 
exceed those in the VTA (Brichta & Greengard, 2014).  
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The SN is divided into two 
functionally distinct subsections, the 
SN pars compacta (SNc) and the SN 
pars reticulata (SNr). The SNc is the 
primary locus of the dopaminergic 
neurons in the SN, and is the site most 
affected by neurodegeneration in PD 
pathology. Within the SNc, the most 
severe neurodegeneration is found in the ventrolateral aspect, particularly in extensions of 
ventral SNc dopaminergic neurons into the SNr, called nigrosomes. The SNr is relatively 
sparse in cells, and is functionally equivalent to the Gpi (Gibb & Lees, 1991; Vogt 
Weisenhorn et al., 2016). There is a third zone distinguished by cytoarchitectonic 
demarcations, the pars lateralis, located laterally and rostral in the SN, although this area 
has drawn relatively little attention in the PD literature (DeMaagd & Philip, 2015; Gibb 
& Lees, 1991).  
The ventral tegmental area (VTA) is located medially to the SN and is just lateral 
to the midline of the brain. Similar to the SN, it has been implicated in a wide range of 
functions including addiction, reward, cognition, and addiction, and is closely connected 
to the limbic system (Johnson & North, 1992). Although the VTA and SN are somewhat 
similar from a macroscopic anatomical perspective, in the pattern of neurodegeneration 
observed in PD, the VTA, i.e. cell group A10, is largely unaffected, while cell group A9 
in the SN is significantly diminished (Vogt Weisenhorn et al., 2016). The cell group A-8 
Figure 2 Location of substantia nigra in midbrain, as 
depicted in Gray's Anatomy (1918). Source: Wikimedia 
Commons, 
https://commons.wikimedia.org/wiki/File:Gray712.png 
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is localized to the retrorubral field, an area of the ventral mesencephalon dorsolateral to 
the SN and caudal to the red nucleus. This area is notable for its interaction with the 
adrenergic system modulating dopamine release in the midbrain (Mejias-Aponte, 2016).  
 
Figure 3 Organization of neuroanatomical structures, as depicted in Gray's Anatomy (1918). Source: Wikimedia 
Commons https://commons.wikimedia.org/wiki/File:Telencephalon-Horiconatal.jpg#/media/File:Gray742.png 
Other nuclei in the BG include the striatum, the pallidum, and the subthalamic 
nucleus (Helie et al., 2013; Stocco et al., 2010). The striatum is a large structure at the 
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base of the forebrain. It is composed of dorsal and ventral subdivision. The dorsal 
striatum is further divided into a caudate nucleus and putamen, while the ventral striatum 
includes the nucleus accumbens and the olfactory tubercle. The pallidum is composed of 
the Gpe and Gpi (DeMaagd & Philip, 2015; Stocco et al., 2010). Considered in terms of 
neural computational processing, the striatum is the input to the BG because it is the 
recipient of major inputs from the entire cerebral cortex. The BG’s outputs are the SNr 
and Gpi, which project to the thalamus (Stocco et al., 2010).  
The striatum is the largest structure of the BG and is situated most laterally. 
Similar to the SN, it has been implicated in a wide range of cognitive and motor 
functions. The dorsal striatum is involved primarily with motor functions, reward 
systems, and neural inhibition  (Stocco et al., 2010). A large white matter tract, the 
internal capsule, separates the two parts of the dorsal striatum. The striatum receives 
input from the cortex and projects it to other targets in the BG, most notable the SN. 
There is also a substantial amount of dopaminergic neurons from the ventral 
mesencephalon which converges upon the striatum, representing the major source of 
dopamine found within the striatum (Stocco et al., 2010; Vogt Weisenhorn et al., 2016; 
Yager et al., 2015). 
Located caudally within the dorsal striatum, the caudate nucleus is implicated in 
motor processes and has been shown to be involved in non-motor processes as well, such 
as rewards and learning systems (Helie et al., 2013; Stocco et al., 2010; Weinberger & 
Dostrovsky, 2011). The caudate nucleus is involved in the pathways that give rise to a 
wide range of neurological diseases, including PD, Huntington’s Disease, attention 
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deficit hyperactivity disorder, Alzheimer’s Disease, obsessive compulsive disorder, 
schizophrenia, and more (DeMaagd & Philip, 2015; Mejias-Aponte, 2016; Stocco et al., 
2010; Vogt Weisenhorn et al., 2016). The putamen, located rostral to the internal capsule, 
regulates movement and influences learning (Helie et al., 2013; Stocco et al., 2010). 
Occasionally the putamen is grouped together with the globus pallidus, and referred to as 
the lentiform nucleus. The list of processes and conditions which involve the putamen are 
just as extensive as the caudate nucleus (Stocco et al., 2010).  
The ventral striatum, composed of the nucleus accumbens and the olfactory 
tubercle, is located lateral to the globus pallidus, and ventral to the dorsal striatum as the 
name suggests. It is intricately connected to the limbic system, and likewise plays a 
crucial role in reward systems and decision making behavior (Stocco et al., 2010). The 
nucleus accumbens contains predominantly GABAergic neurons, which are modulated 
by dopaminergic projections primarily from the VTA (Yager et al., 2015). It is indirectly 
associated with the degeneration of PD, but plays a direct role in rewards learning and 
addiction (Mejias-Aponte, 2016; Yager et al., 2015). The olfactory tubercle is responsible 
for transmitting sensory data relating to olfaction to relevant areas of the brain, but there 
is inconclusive research to show whether the ventral striatum participates in olfaction or 
not (Yager et al., 2015). Interestingly, anosmia is a symptom of PD so there may yet be a 
connection (DeMaagd & Philip, 2015). 
Located medial to the striatum lies the globus pallidus. This structure is part of the 
telencephalon, and is has close functional ties to the subthalamic nucleus and several of 
the BG nuclei. Latin for ‘pale globe’, its name is possibly a reference to the high 
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proportion of myelination noted in the region, although the ultimate origin of the name is 
uncertain (Vogt Weisenhorn et al., 2016). The globus pallidus is also divided into two 
sub-regions by a sheet of tissue known as the medial medullary lamina, the globus 
pallidus internus (Gpi) and the globus pallidus externus (Gpe). Each nucleus is entirely 
encased in a myelinated covering. The Gpe is closest in proximity to the striatum, and the 
Gpi is situated medially and slightly ventrally to the Gpi (Helie et al., 2013; Weinberger 
& Dostrovsky, 2011). Collectively, the Gpe and Gpi work in conjunction with other BG 
nuclei and are involved in the production of voluntary movement. The Gpe and Gpi both 
receive input from the striatum, and the Gpi additionally receives input from the 
subthalamic nucleus. There is also a lesser degree of communication with the SN. The 
striatal afferents to the globus pallidus predominantly GABAergic, while the SN axons 
are dopaminergic. Both parts of the globus pallidus ultimately project to the thalamus 
(Helie et al., 2013). Despite being physically separated by a tract of white matter, the SNr 
and Gpi are alike in cytologic composition as well as function. This leads some 
researchers to consider the two as a single heterogenous entity (Stocco et al., 2010). 
There is a third pallidal component which is not often discussed in the PD 
literature concerning the midbrain dopaminergic system, the ventral pallidum. This is 
located in the substantia innominata, and relays information from the ventral striatum to 
the thalamus. The ventral pallidum contains a strong pleasure center, and is likely closely 
associated with the nucleus accumbens. This structure provides a link between the cortex 
and limbic system (Berridge & Kringelbach, 2015).  
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The final structure in the BG is the subthalamic nucleus (STN). This structure is 
located ventral to the thalamus, and dorsal to the SN. It receives connections from the 
cortex, and transmits information to the Gpi (Helie et al., 2013). Dopamine acts on the 
STN to produce a range of effects, while the STN itself is composed mainly of 
glutamatergic output. The STN is believed to be a pacemaker region, which emits tonic 
impulses that coordinate activity in the rest of the BG (Weinberger & Dostrovsky, 2011). 
 
Basal Ganglia Connections 
The substantia nigra (SN) and the dopamine system it is part of have a multitude 
of functions. Dopamine is not the only neurotransmitter of note in the substantia nigra. 
Dopamine is released often in conjunction with GABA or glutamine (Vogt Weisenhorn et 
al., 2016; Weinberger & Dostrovsky, 2011). It has also been found that there is 
significant interaction between adrenergic neurotransmitters and the midbrain dopamine 
system (Mejias-Aponte, 2016). The dopamine system extends far beyond the SN, it 
incorporates the various midbrain structures and their projections to the thalamus and to a 
range of cortical areas (Mejias-Aponte, 2016; Vogt Weisenhorn et al., 2016; Helie et al., 
2013). There is also an extensive body of research investigating dopamine’s role in other 
neurological disorders and psychiatric conditions. Dopamine and the basal ganglia have 
been shown to be involved in PD, Huntington’s Disease, schizophrenia, addiction, and 
quite a few more disorders (Mejias-Aponte, 2016; Vogt Weisenhorn et al., 2016; 
DeMaagd & Philip, 2015). It is evident that the BG are at a crossroads of many 
information processing pathways involved in coordination of movement, emotional 
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expression, reward based learning, and cognitive function (Mejias-Aponte, 2016; Helie et 
al., 2013).  
 The ventral mesencephalon has extensive connections to the cortex, striatum, and 
other surrounding brain areas. The complex web of connections use an array of 
dopamine, GABA, and glutamate, sometimes with receptors for multiple 
neurotransmitters at a single synapse (Mejias-Aponte, 2016; Vogt Weisenhorn et al., 
Figure 4 A schematic representation of the circuitry of the basal ganglia. A “+” indicates excitatory 
connections, “-“ indicates inhibitory connections. Dopaminergic, glutamatergic, and GABAergic connections 
are shown respectively in light, medium, and dark grey. SP represents the striatopallidal connection, SN 
represents the striatonigral connection, and IN represents a striatal interneuron. “Da” indicates the 
dopaminergic connection from the SNc to the striatum. In addition to the information shown in the figure, the 
dopaminergic projections from the SNc inhibit the striatopallidal pathway, and exert and excitatory effect on 
the striatonigral neurons. Reproduced from Stocco et al. 2010. 
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2016). Before delving into the chemistry of the synapses, it is helpful to envision the 
general layout of the BG neural network in terms of the flow of information. The major 
input to the BG processing circuit is the striatum and the output is from the Gpi or SNr. 
Input information originates in the cortex, and output is projected mostly to the thalamus. 
There are three main pathways which information can take through the BG circuit, called 
the direct, indirect, and hyperdirect pathways (Helie et al., 2013). In terms of function 
within the circuit, the SNr and Gpi are often considered one entity, what Stocco (2010) 
refers to as the output nuclei.  
 The direct pathway transmits cortical information to the Gpi via the striatum. The 
term ‘direct’ is used because the striatal neurons project directly to the output nuclei, the 
Gpi and SNr (Stocco et al., 2010). The striatal projections are mostly medium spiny 
neurons (MSNs). On average, 5,000-10,000 cortical neurons converge on one striatal 
MSN. The striatonigral MSNs in this pathway express a particular type of dopamine 
receptor, D1 (Helie et al., 2013).  
 In the indirect pathway, cortical information is routed through the striatum, then 
striatal MSNs project to the Gpe, which in turn projects to the output nuclei (Stocco et al., 
2010; Weinberger & Dostrovsky, 2011). This pathway is also very convergent, with the 
same proportion of cortical neurons converging on striatal MSNs as in the direct pathway 
(Helie et al., 2013).  The striatopallidal neurons in this pathway are characterized by 
expression of dopamine receptor D2 (Helie et al., 2013; Stocco et al., 2010). 
 The hyperdirect pathway goes from the cortex, to the STN, and ends at the output 
nuclei. Stocco (2010) considers the STN a second input to the BG circuit because of the 
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significant quantity of cortical inputs that converge there (Stocco et al., 2010; Weinberger 
& Dostrovsky, 2011). This indirect pathway is the fastest connection between the cortex 
and the output nuclei, because it the cortex can interact with the STN over a single 
synapse (Helie et al., 2013). It is believed that the hyperdirect pathway is responsible for 
a preliminary and wide ranging inhibition of motor processes, which work in tandem with 
the dis-inhibitory information from the direct and indirect pathways in order to produce 
smooth, volitional motion (Nambu et al., 2002). 
 The three pathways listed here are not the only connections within the BG, 
although they constitute the majority of the flow of information within the BG circuit. 
Smaller connections have been found between the various nuclei of the BG, with a decent 
degree of feedback processes (Stocco et al., 2010). Whereas the three pathways listed 
above proceed from cortex, to the BG, then to the thalamus, the feedback proceeds in the 
opposite direction. Some of the more common feedback pathways include Gpe 
projections to the striatum, STN projections to the Gpe, and connections from the 
thalamus to the striatum (Stocco et al., 2010; Weinberger & Dostrovsky, 2011). The 
thalamo-striatal projections synapse on MSNs as well as another prominent striatal 
neuron class, the tonically active neuron (TAN) (Helie et al., 2013). The TANs are large-
bodied striatal interneurons which contribute to plasticity and learning, and are 
cholinergic. They represent another interface between the dopaminergic system of the BG 
and other neurotransmitter systems in the brain (Pisani et al., 2001). Another feedback 
pathway, the nigrostriatal feedback from the SNc to the striatum, is of particular 
relevance to PD. This route is composed of axons of dopaminergic cells in the SNc and 
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therefore is one of the most directly impeded pathways in the progression of PD (Stocco 
et al., 2010).  
 Dopamine has a regulatory role in the BG and is essential for proper integration of 
the cognitive and motor processes that result in normal movement. The effect of 
dopaminergic cell death found in PD pathology has traditionally been explained in terms 
of the ‘rate model’ (Weinberger & Dostrovsky, 2011). This model has been a useful 
guide for PD researchers, as it is able to account for the bradykinesia and the other 
symptoms which distinguish PD. The premise, as laid out by Weinberger and Dostrovsky 
(2011), is that dopaminergic inputs from the SN inhibit the striatum. Losing this 
inhibition leads to striatal hyperactivity, which increases activity of the output nuclei. 
These output nuclei have a GABAergic inhibitory effect on the thalamus, which leads to 
thalamic hypoactivity. This essentially makes the thalamic link from the BG to the motor 
cortex less excitable, resulting in bradykinesia.  
While the model has high explanatory power, in reality this is an 
oversimplification of the system. Research has found that dopamine has a wide range of 
effects from inhibitory to excitatory, and it can act on both pre- and postsynaptic 
terminals to affect a different response. To add complexity, dopamine is just one of many 
neurotransmitter systems which has been identified within the BG (Mejias-Aponte, 2016; 
Stocco et al., 2010; Vogt Weisenhorn et al., 2016; Weinberger & Dostrovsky, 2011). 
Furthermore, recent lines of research have explored the possibility that the firing pattern 
and oscillations of baseline neuronal membrane potential have a more profound effect on 
BG function than the rate of neuronal firing (Weinberger & Dostrovsky, 2011).  
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Dopamine Biology  
Despite the intricate understanding of the 
connections within the brain and the effects of 
depleted dopamine, the underlying pathology 
which leads to dopaminergic neuronal death is 
still poorly understood. Many of the proposed mechanisms involve aggregates of α-
synuclein in a pattern similar to Lewy Body Dementia (DLB) and Alzheimer’s Disease, 
although more recently several models have been proposed which involve other pathways 
to degradation (Plaas et al., 2008; Stuendl et al., 2016). An area which has garnered much 
attention recently is the effect of oxidative stress in the BG as a result of local cellular 
biology and dopamine metabolism (Vogt Weisenhorn et al., 2016). It is also likely that 
there is not a single method of degeneration in PD, but rather the dopaminergic cell 
toxicity results from a combination of several stressors (DeMaagd & Philip, 2015; Vogt 
Weisenhorn et al., 2016). 
An understanding of dopamine and the other related neurotransmitters on the 
molecular level is helpful when envisioning the role of these mediators in the neural 
microenvironment. Dopamine is a catecholamine, a class of molecules consisting of a 
1,2-dihydroxybenzene ring with an amine side chain. Variations in the amine side chain 
distinguish the three main catecholamines: dopamine, epinephrine, and norepinephrine. 
These molecules can be interconverted by cellular enzymes (Broadley, 2010).  
The dopamine synthesis pathway is a network of enzymes and substrates, which 
begins with the amino acid L-phenylalanine. This substrate can undergo one of two 
Figure 5 Structure of dopamine. Reprinted 
from Wikimedia Commons 
https://commons.wikimedia.org/wiki/File:Dopa
mine.svg 
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reactions. The first, catalyzed by the enzyme aromatic L-amino acid decarboxylase 
(AADC), yields phenethylamine, which is then acted upon by phenylethanolamine N-
methyltransferase (PNMT) and yields N-methylphenethylamine, a trace amine and 
isomer of amphetamine. Amphetamine has a wide range of actions in the central nervous 
system, including addiction and appetite modulation. The second reaction undergone by 
L-phenylalanine is catalyzed by an aromatic amino acid hydroxylase family enzyme 
Figure 6 Dopamine metabolic pathways. Source: Wikimedia Commons 
https://commons.wikimedia.org/wiki/File:Catecholamine_and_trace_amine_biosynthesis.png 
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(AAAH), phenylalanine hydroxylase, yielding L-tyrosine. There are two branches of 
reactions for L-tyrosine. The first is catalyzed by AADC, converting L-tyrosine to p-
tyramine. This product is further metabolized into various trace amines, present in 
insignificant quantities in the human brain (Broadley, 2010). L-tyrosine can interact with 
a different AAAH enzyme, tyrosine hydroxylase, to produce L-DOPA. Tyrosine 
hydroxylase is the rate limiting step in the main pathway of dopamine synthesis 
(Broadley, 2010).  
 
The molecule L-DOPA, also known as levodopa or L-3,4-
dihydroxyphenylalanine, is a useful molecule for PD research and treatment. It is able to 
cross the blood-brain barrier, which dopamine cannot cross. This makes L-DOPA a 
simple and effective access point to the dopamine synthesis cascade, which allows 
efficient control over dopamine levels in-vivo. L-DOPA undergoes a decarboxylation 
reaction catalyzed by AADC to yield dopamine. Dopamine, more formally denoted as 
3,4-dihydroxyphenethylamine, is primarily synthesized from L-DOPA by the pathway 
laid out above, but another pathway exists (Broadley, 2010; Wang et al., 2014).  
The p-tyramine resultant from the reaction of L-tyrosine catalyzed by AADC is 
traditionally considered a high-yield source for trace amines, however recent research has 
found an enzyme localized to the brain which converts p-tyramine to dopamine. This 
enzyme is an isoform of cytochrome P450, labeled CYP2D6. This is a minor synthesis 
pathway, but has been found to correlate loosely with dopamine depletion in the brain. 
Wang, Dong, and Yue (2014) report that CYP2D6 expression is 40% lower in the frontal 
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cortex, cerebellum, and hippocampus of patients with PD compared to unaffected 
patients. Given cytochrome P450’s crucial role in toxicology, it is possible that CYP2D6 
has a neuroprotective role, and when its expression is diminished the brain is susceptible 
to environmental and endogenous neurotoxins (Wang et al., 2014).  
There are several metabolic breakdown pathways available for dopamine. 
Dopamine is a substrate for synthesis of the other catecholamines, epinephrine and 
norepinephrine. Dopamine reacts with the enzyme dopamine-β-hydroxylase as a catalyst 
to yield norepinephrine. PNMT then catalyzes a reaction with norepinephrine to produce 
epinephrine (Broadley, 2010).  
Another option is for dopamine to interact with the enzyme catechol O-
methyltransferase (COMT), which yields the trace amine 3-methoxytyramine. This amine 
can react with the enzyme monoamine oxidase (MAO) in conjunction with aldehyde 
dehydrogenase (ALDH) which produces homovanillic acid (HVA). HVA has no known 
biological activity; it enters the bloodstream and is filtered out by the kidneys. Both 
MAO-A and MAO-B isoforms are known to react with dopamine, although there may be 
a slight preference for dopamine to interact with MAO-B (Broadley, 2010).  
The final degradation pathway for dopamine begins with a reaction with MAO 
that results in DOPAL formation. DOPAL, short for 3,4-dihydroxyphenylacetaldehyde, is 
believed to be cytotoxic, thus its buildup could be a possible route of neurotoxicity in PD 
(Broadley, 2010; Miyazaki & Asanuma, 2008). DOPAL undergoes a reaction catalyzed 
by COMT to produce HVA, which effectively neutralizes the neurotoxic threat of 
DOPAL (Broadley, 2010).  
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Dopamine is also potentially neurotoxic. At high levels, dopamine interacts with 
other dopamine molecules and is oxidized to form DOPA quinones as well as reactive 
oxygen and nitrogen species. These compounds can harm the cell in which they were 
produced by interfering irreversibly with protein structure. DOPA quinones have been 
found to react with proteins, forming 5-cysteinyl-catechols that can hinder protein 
function. In this way, dopamine-induced oxidative stress can harm cells (Miyazaki & 
Asanuma, 2008). 
The mechanism responsible for neurotoxicity in the dopaminergic neurons of the 
SNc is still an area of ongoing investigation. Research into the cause of cell death has 
often dealt with α-synuclein aggregation within cells, and new data shows the 
involvement of genetic and epigenetic factors such as miRNA silencing and selective 
expression of transcription factors (Hernandez-Rapp, Rainone, & Hébert, 2017; Vogt 
Weisenhorn et al., 2016). Researchers are also pursuing consistently reliable biomarkers 
or other indicators which would indicate definitively whether a patient has PD or not, and 
also indicate the degree of disease progression (Breen & Lang, 2017).  
At present, there still is not a cure for PD. Some speculate that this is due to the 
high degree of degeneration in the SNc before PD is diagnosed, as if there is a critical 
threshold of degeneration past which the damage is irreparable and unable to be 
compensated (DeMaagd & Philip, 2015; Vogt Weisenhorn et al., 2016). It is essential to 
detect PD early and initiate therapies before the cell death has progressed past the critical 
point such that quality of life may be maintained as long as possible (Breen & Lang, 
2017; DeMaagd & Philip, 2015).  
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PUBLISHED STUDIES 
The molecular foundation underlying PD is intricately complex. In order to 
understand the etiology and pathology of PD, it is helpful to understand the 
microenvironment of the ventral mesencephalon. First this paper will consider 
heterogeneity of the dopamine system and how it relates to the preferential susceptibility 
of the SNc. Next the paper will examine the connections within the BG circuitry and 
explore how their firing patterns influence pathology. Then it will examine the dopamine 
system’s interactions with other neurotransmitter systems in the brain, notably the 
adrenergic system. The mechanism of dopaminergic neuronal degradation will be 
considered next, from several perspectives including oxidative stress and α-synuclein 
aggregation. This section of the paper will conclude by addressing the possibility of early 
detection of PD via genetic biomarkers and imaging studies.  
Heterogeneity of Dopaminergic Subpopulations  
The dopamine system which has garnered so much attention for the past few 
decades is still an active area of research. One of the main questions which researchers 
are seeking to explain is the asymmetric susceptibility of dopaminergic neurons, i.e. why 
do the neurons in the SNc degrade while other dopaminergic neurons are nearly 
untouched. Furthermore, there is disparity within the SNc, where the ventrolateral tier, 
the nigrosome, is significantly more degraded than the dorsomedial tier (Gibb & Lees, 
1991; Vogt Weisenhorn et al., 2016).  
 Vogt Weisenhorn et al. (2016) provides a thorough account of dopaminergic 
neuronal differentiation within the ventral mesencephalon. Dopaminergic neurons in the 
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ventral mesencephalon can be differentiated according to their efferent projection 
patterns. There are three efferent pathways. Slight overlap exists between the pathways’ 
targets, but the main target of each tract is distinct. The mesostriatal pathway projects to 
the dorsal striatum, the mesolimbic pathway projects to the ventral striatum, and the 
mesocortical projects to various cortical targets. The origin of these pathways correlates 
spatially with the A9 and A10 cell groups. Group A9, localized to the SN, is associated 
with the mesostriatal pathway, whereas A10 is localized to the VTA and is associated 
with the mesolimbic and mesocortical pathways. Neurodegeneration is largely limited to 
the mesostriatal pathway, which further highlights that cellular differences exist within 
the dopaminergic family (Vogt Weisenhorn et al., 2016).  
  Differentiation also exists in these dopaminergic neurons’ afferent projections. 
The SN and VTA receive innervation from a wide range of brain structures; notably there 
is a reciprocal connection between the ventral mesencephalon and the striatum 
(Weinberger & Dostrovsky, 2011; Yetnikoff et al., 2014). Just as the VTA sends 
mesolimbic efferents to the ventral striatum, the ventral striatum has afferent projections 
to the VTA. Similarly, the SNc receives afferent innervation from the striatum. These 
afferents interact most with the dorsal SNc, but a significant degree of afferents innervate 
the ventral tier of the SNc as well. In PD pathology, deterioration beyond the SNc is first 
noted in the lateral striatum, which is predicted by the reciprocal connection along the 
mesostriatal pathway  (Vogt Weisenhorn et al., 2016).  
 Further differentiation exists among the dopaminergic ventral mesencephalic 
neurons in terms of their molecular environment. Many of the dopaminergic neurons 
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exhibit multiplexed neurotransmission, meaning they co-release GABA or glutamate 
along with dopamine (Mejias-Aponte, 2016). In the VTA, between 5-20% of 
dopaminergic neurons express the vesicular glutamate transporter-2, whereas this 
transporter is much less common in the SNc and it is only found laterally (Vogt 
Weisenhorn et al., 2016).  
 The neurotransmitter GABA is much more common in the SNc compared with 
glutamate, which is mostly localized to the VTA (Brichta & Greengard, 2014). The 
dorsal striatum is replete with GABA induced synaptic currents, thus implying that there 
is ample GABA activity in the SNc (Vogt Weisenhorn et al., 2016). However, in the vast 
majority of multiplexed dopamine-GABAergic neurons, neither the vesicular GABA 
transporter nor GABA synthetic enzymes have been detected (Kim et al., 2015).  Vogt 
Weisenhorn et al. (2016) suggests that GABA is synthesized by a non-canonical pathway, 
and is released in tandem with dopamine in the same vesicles. The transporter vesicular 
monoamine transporter-2 is required for GABA release in these cells. In the absence of 
this transporter, dopaminergic activity is detected but not GABA activity.  
As for the synthesis of GABA without the traditional enzymes, Kim et al. (2015) 
propose a possible synthetic pathway involving aldehyde dehydrogenase 1a1 
(ALDH1a1). This is an attractive explanation due to the fact that ALDH1a1 is highly 
expressed in the dopaminergic neurons in the SNc, and has been shown to be integral to 
the co-release of dopamine and GABA (Vogt Weisenhorn et al., 2016).  
In contrast to GABA, glutamate is not co-packaged with dopamine. It is released 
at a physically separate space than dopamine and is not contained in the same vesicles as 
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dopamine. The intricacies of the multiplexed GABA-glutamate-dopamine release 
patterns allow for the system to be very specific, enhancing the range of dopaminergic 
signals which regulate complex behavior (Mejias-Aponte, 2016; Vogt Weisenhorn et al., 
2016). This view is strengthened by the finding that ALDH1a1, very common in the 
ventral mesencephalic dopaminergic cells, is intricately tied to rewards pathways that 
govern alcohol intake and associated addiction behavior (Kim et al., 2015).  
Gene expression provides another point for contrasting the nature of midbrain 
dopaminergic neurons. There is a 97-99% similarity in the gene expression of VTA 
dopaminergic neurons compared to those in the SNc, which means that 1-3% difference 
remains and could potentially account for the profound difference in vulnerability of 
these two neuron populations in PD pathology (Brichta & Greengard, 2014). 
Differentially expressed genes were found to be involved in a wide range of cellular 
functions, such as dopamine biology, neuronal activity, neuronal survival, and 
transcription factors. The genes in each category are not entirely absent in one while 
present in another cell type, rather the differences in expression are generally related to a 
strong vs. weak degree of expression (Vogt Weisenhorn et al., 2016).  
Poulin et al. (2014) studied 96 genes involved in dopamine biology in the ventral 
mesencephalon, and used their findings to group dopaminergic neurons into categories. 
There were two general archetypes, DA1 and DA2, with further subdivisions of DA1A, 
DA1B, and DA2 group A-D (DA2A-D). The categorization of archetypes and subtypes, 
while based in genetic data, correlated well with the spatial distribution of cells.  The 
DA1 cluster was localized to the SN, whereas DA2 was in the VTA (Poulin et al., 2014). 
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Within the SN, DA1A was found mostly in the SNc and constitutes the neurons which are 
most susceptible to degradation in PD pathology (Gibb & Lees, 1991; Vogt Weisenhorn 
et al., 2016).  A unique finding of subset DA1A is that it expresses the highest levels of 
Kcnj6 (aka Girk2), a G-protein regulated potassium channel. It is possible that the 
selective degeneration in this region is linked to expression of this channel (Poulin et al., 
2014).  
The Kcnj6 channel is related to neural activity regulation. In a study done with 
mice, researchers found that mice with a homozygous knockout of Kcnj6 began losing 
SNc neurons on day 7 post-natal, and at 90 days had lost almost 70% of the SNc 
dopaminergic neurons (Brichta & Greengard, 2014). It seems contradictory that in mice 
without this gene there was significant degeneration, while high expression of this 
channel is also linked to degeneration as found in Poulin et al. (2014). This area is of 
interest to future research. 
Another interesting finding from this line of research is that DA1A subtype is 
characterized by high expression of ALDH1a1. ALDH1a1 is believed to have a 
neuroprotective effect, as it oxidizes the neurodegenerative dopamine metabolite DOPAL 
into HVA (Broadley, 2010). High DOPAL concentration has been shown to promote α-
synuclein aggregate formation, which is effectively prevented by ALDH1a1. However, 
these cells in the SNc are still especially vulnerable in PD, so there must be other patterns 
of degeneration involved which overpower the ALDH1a1 neuroprotective effect (Vogt 
Weisenhorn et al., 2016). 
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Whereas DA1A was found to have a unique feature conferring toxicity, DA2 was 
found to uniquely express the transcription factor Otx2. The study authors found that 
Otx2-expressing cells mitigated the toxic effect of MPTP, a known neurotoxic 
compound. In contrast, DA1A cells were susceptible to MPTP induced toxicity (Anderegg 
et al., 2015). The DA2 group was also found to express Fzd1, a gene which encodes a 
receptor in the Wnt1 cascade. Fzd1 is another neuroprotective agent which protects cells 
from cytotoxins as well as protects against degeneration if certain transcription factors are 
lost, e.g. En-1. Fzd1 is not expressed in appreciable levels in the DA1A subtype (Poulin et 
al., 2014). 
The post-translational modification of proteins differs between populations of 
dopaminergic neurons in the ventral mesencephalon. There is not much written in the 
literature about this phenomenon, so it merits future study. However there are some 
preliminary studies which indicate that the dopamine transporter Slc6a3 is glycosylated 
quite often in the SNc, while the glycoprotein is less common in the VTA (Vogt 
Weisenhorn et al., 2016). The glycosylated form is highly active and is present in about 
20% of SNc dopaminergic neurons (Brichta & Greengard, 2014). 
The genetic findings of Poulin (2014) are useful in differentiating dopaminergic 
subtypes, but they fall short of providing conclusive evidence for a genetic marker of PD. 
The genes which are traditionally associated with PD pathology (α-synuclein, Parkin, 
Pink1, Lrrk2, etc.) were shown to be ubiquitously expressed throughout the ventral 
mesencephalon, and could not distinguish a unique subpopulation (Poulin et al., 2014). 
Therefore, it is unlikely that that a single gene mutation could be linked to the 
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degradation pattern characteristic of PD. This has led some researchers to propose a 
multiple-hit hypothesis among the genes, where no single mutation would contribute to 
degeneration but several in conjunction could have deleterious effects (Vogt Weisenhorn 
et al., 2016).  
Basal Ganglia Circuit 
The overt motor symptoms of PD are rooted in the heterogeneity of the dopamine 
system. The classic conception of PD pathology was that the loss of dopaminergic 
inhibition in the striatum led to hyperactivity, which would increase the rate that the 
striatum sent information to the SNr and Gpi. The output nuclei tonically inhibit the 
thalamus via GABA action, so an increase in stimulation from the output nuclei leads to a 
decrease in thalamic excitability. The end result is that the thalamus relays less 
information to the motor cortex, which gives rise to bradykinesia (DeMaagd & Philip, 
2015; Weinberger & Dostrovsky, 2011; Yetnikoff et al., 2014).  
Weinberger and Dostrovsky (2011) propose a slightly different version of this 
model which generates the motor symptoms of PD. This model, based on data from 
electrophysiological recordings of the cortex and BG circuit in both animal models and 
human patients, focuses on the alterations in firing patterns and baseline oscillations in 
membrane potential of neurons which occur secondary to chronic dopamine depletion. 
Electrodes were implanted in patients’ brains which offered therapeutic regulation to 
patients, and allowed researchers to manipulate the local field potentials at the 
implantation location, i.e. the STN and Gpi. Animal models were constructed where 
monkeys were treated with MPTP and rats were treated with 6-hydroxydopamine to 
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artificially degrade the SNc and record the results with electrodes. In a dopamine 
depleted state, there is increased functional connectivity between the cortex, STN, and 
globus pallidus. It seems that increased synchrony in neuronal firing, and increased 
oscillatory firing within the BG contribute significantly to PD pathology (Weinberger & 
Dostrovsky, 2011; Yetnikoff et al., 2014).  
Chronically depleted dopamine levels in the striatum lead to a surfeit of 
synchronized oscillatory firing within the BG-cortical loops. This oscillation can be 
observed and induced in vivo in PD patients who withdraw from anti-parkinsonian 
medications (Stocco et al., 2010; Weinberger & Dostrovsky, 2011; Yetnikoff et al., 
2014). The oscillations occurred most prominently in the STN and globus pallidus, and 
align with one of two frequencies (Weinberger & Dostrovsky, 2011). The tremor 
frequency is around 4-6Hz (DeMaagd & Philip, 2015), and takes precedence in PD 
patients whose main symptom is tremor, whereas the beta frequency is around 11-35Hz. 
The beta frequency was also observed in rats in the 6-hydroxydopamine model. These 
effects can be rapidly reversed by administering dopamine medications. In the dopamine 
depleted state, MSNs express a higher degree of gap junctions which electrically couple 
them to neighboring cells, facilitating synchronization of firing. The exact mechanism 
that links synchronization to pathology is uncertain, but the observed alteration in firing 
pattern is unique to neurons undergoing PD degeneration (Weinberger & Dostrovsky, 
2011).  
MSNs in the striatum are more excitable in the absence of dopamine. Under 
normal conditions, their membrane potential is very polarized. The potential is 
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determined by inward movement of rectifying potassium currents which maintain a 
hyperpolarized state for the membrane. Action potentials can only occur when the 
summation of concurrent impulses overcome the rectifying current and cross the neuron’s 
threshold. Dopamine inhibits MSN excitability by promoting the hyperpolarization of the 
MSN membrane (Weinberger & Dostrovsky, 2011).  
Altogether, there are 5 main isoforms of the dopamine receptor, D1-5, and each 
has a marginally different effect on cellular function. The distribution of these receptors 
in the BG is not uniform (Brichta & Greengard, 2014). Dopamine induces its inhibitory 
effect through interaction with the D1 receptor. D1 is found on the post-synaptic terminus 
of striatal MSNs and is a G-protein coupled receptor (GPCR). Studies have found that 
antagonists of this receptor effectively silence the MSN. Dopamine has an additional 
inhibitory effect on the presynaptic terminus of neurons projecting to the striatum, where 
dopamine inhibits glutamate release by interacting with the D2 receptor. Loss of 
dopamine reduces this striatal inhibition by both the D1 and D2 receptor, allowing a 
much greater proportion of cortical input to enter the BG circuit (Weinberger & 
Dostrovsky, 2011).  
In the Gpe, dopamine has an excitatory effect. This is accomplished via 
interaction with presynaptic D2 receptors on striatopallidal terminals, which works to 
inhibit the release of GABA. Dopamine has a postsynaptic action here as well, mediated 
by the D4 receptor, which suppress GAGA-induced currents. In the Gpi and SNr, 
dopamine has an opposite effect. It activates presynaptic D1-like receptors, which 
induces greater GABA release and reduces Gpi neuronal activity. While the action of 
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dopamine in the Gpe and Gpi are seemingly incongruous, it appears that the overall 
action is one that inhibits transfer of cortical inputs. In the pathological state, the 
dopaminergic inhibition decreases and there is a higher degree of connectivity 
(Weinberger & Dostrovsky, 2011).  
The STN is a pacemaker for impulses in the BG. It is dense with glutamatergic 
neurons that can generate action potentials without synaptic input. It is believed that this 
is caused by voltage-gated sodium channels (Yetnikoff et al., 2014). Activation of D1 and 
D2 receptors in the STN encourages tonic firing patterns in this region. In the normal 
state this neuron population has a high degree of tonic firing, with little burst activity, a 
finding which is reversed in PD pathology. The sodium channels which allow for tonic 
firing are inactivated by autonomous firing in the STN, and require feedback from the 
Gpe to reactivate these channels. This feedback loop is thrown off balance in the absence 
of dopamine, and the synchronized pattern of pathological firing results (Weinberger & 
Dostrovsky, 2011).  
The excitatory STN input to the Gpe under normal conditions constitutes the main 
control factor for Gpe firing, with inhibitory striatal input taking secondary prominence. 
In the dopamine depleted state this input pattern switches, and striatal inhibition is the 
main input to the Gpe. This contributes to the irregular firing patterns characteristic of PD 
(Weinberger & Dostrovsky, 2011). 
The data from PD patients confirms the findings of Weinberger and Dostrovsky 
(2011). Measured by deep brain electrodes and electroencephalogram (EEG), PD patients 
show a high degree of synchronized firing in the STN and Gpi, with notable burst firing 
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in each nucleus at the beta frequency (11-35Hz). This effect is greatly reduced by anti-
parkinsonian medications. The inhibition afforded by dopamine is essential for proper 
functioning of the system; in its absence the synchronized oscillations of the BG firing 
patterns impede proper processing of motor signals (Weinberger & Dostrovsky, 2011). 
Interface of Adrenergic and Dopamine Systems  
In addition to the GABAergic and glutamatergic connections outlined above, the 
dopamine system is very closely tied to the midbrain adrenergic system. Mejia-Aponte 
(2017) succinctly outlines the interface between the two, and the implications of 
adrenergic modulation in dopaminergic dysregulation. Epinephrine and norepinephrine 
are abundant neurotransmitters in the brain, and act through several adrenoceptors. In 
general, α1, and β1-3 adrenoceptors are considered excitatory, whereas α2 and occasionally 
β2 are inhibitory. All the receptors are GPCRs. Developing an understanding of the 
function of this system could give insight to possible routes of future treatment, or 
compensatory mechanisms available in the brain as dopamine degrades.   
The adrenergic innervation of the ventral mesencephalic dopamine complex arises 
in the brainstem adrenergic nuclei and in the locus coeruleus. Norepinephrine afferents 
originate in cell groups A1 and A2, which correspond to the caudal ventrolateral medulla 
and the solitary tract nucleus, respectively. Epinephrine afferents come from the cell 
group C1, located in the rostral ventrolateral medulla (Dahlstroem & Fuxe, 1964).  Most 
of the adrenergic axons innervating the dopaminergic system interact via classical 
synapses, with a lesser proportion interacting via glia processes, and a smaller proportion 
with gap junction interfaces. The adrenergic axons also interact with non-dopaminergic 
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neurons in the ventral mesencephalon although these associations are yet uncertain in 
function. In the SN, the dopaminergic and non-dopaminergic neurons are clearly 
delineated, but in the VTA it seems they are not segregated (Mejias-Aponte, 2016). 
The ventral mesencephalon dopaminergic neurons express the excitatory α1 
adrenoceptors most prominently. Analysis of mRNA in these cells found little evidence 
for α2 and β2 expression. However, experimental techniques with autoradiography and 
immunohistochemistry found evidence for both α and β receptor expression in this 
region. The full range of adrenoceptors has been found in the ventral mesencephalic 
dopaminergic neurons, albeit not all by a single technique. It is still uncertain whether the 
adrenoceptors are localized to the pre- or postsynaptic terminal, or if their distribution is 
general. In dopaminergic neurons, α1 receptors have been found in both glutamatergic as 
well as GABAergic terminals, which is indicative of pre-synaptic adrenergic modulation 
of these neurotransmitters’ signaling (Velásquez-Martínez et al., 2015). Similarly, α2 
adrenoceptors have been found in the VTA and SN. The effect of this receptor is 
generally post-synaptic, but this has not been conclusively confirmed by research. The α2 
receptors found on non-dopaminergic neurons in the ventral mesencephalon indicate a 
possible route by which adrenergic inputs can indirectly regulate dopaminergic neurons 
via a non-dopaminergic modulator (Mejias-Aponte, 2016).  
The adrenoceptors are not unique to neurons. Adrenoceptor α1 and the 
norepinephrine transporter (NET) have both been observed in glia. Studies have also 
found α2 and the β receptors expressed in microglia and astrocytes in the midbrain. This 
finding is of interest, because glia are known to play a role in maintain the apposition of 
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the synaptic cleft in noradrenergic terminals. Further research is needed to elucidate the 
role of glia in midbrain norepinephrine biology (Mejias-Aponte, 2016).  
Under normal conditions, midbrain dopaminergic neuron impulses occur at 
regular intervals with occasional burst patterns. The bursts of action potentials effectuate 
a large-scale release of dopamine at the axon terminals. These bursts are often a response 
to behavioral circumstances, such as a response to a conditioned stimulus (Friston et al., 
2014; Yetnikoff et al., 2014). Several adrenergic drugs have been shown to alter the 
firing patterns of the dopaminergic neurons. For example, the α2 agonist clonidine did not 
affect the firing rate of DA neurons but it increased firing regularity. Idazoxan and 
piperoxine, on the other hand, both interact with α2 to antagonize the effects of clonidine 
and increase occurrence of burst firing. As for decreasing the firing rate, prazosin and 
isoprotenerol were shown to accomplish this via the α1 and β adrenoceptors, respectively 
(Mejias-Aponte, 2016).  
Three neuromodulation mechanisms were described for the interaction of 
norepinephrine and glutamate release. Norepinephrine was observed to potentiate 
glutamate release, in that it increased the overall trend of glutamate release independently 
of the spontaneous activity of the neuron. In other cases, norepinephrine enhanced 
glutamate release, causing larger quantities of the neurotransmitter to be secreted. Lastly, 
norepinephrine was noted to have a glutamate suppression character as well, decreasing 
the total release quantity. The exact receptors responsible for each effect have not been 
determined, but it appears that the excitation modulation is sensitive to α1 receptor 
agonists, and suppression was insensitive to α1, α2, and β adrenoceptor antagonists. 
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Furthermore, electrical stimulation of the A2 and C2 cell groups induced a response in 
the ventral mesencephalic dopaminergic neurons, and the response involved both 
inhibitory and excitatory elements (Mejias-Aponte, 2016).  
In ex-vivo conditions, norepinephrine was found to have an excitatory effect on 
dopaminergic neurons. Acting through the α1 receptor, norepinephrine elicited 
depolarization in 36% of dopaminergic neurons, which led to an increase in firing rate. 
This effect can be reproduced with the adrenergic drug phenylephrine, an α1 agonist, and 
inhibited by prazosin, an α1 antagonist (Mejias-Aponte, 2016). 
 The α1 receptor appears to be involved in two ion currents’ regulation. Activation 
of the receptor decreases calcium-activated potassium channel currents in the 
dopaminergic neuron, while it increases hyperpolarization-activated cation currents. 
Altogether, this receptor evokes an increase in burst firing (Mejias-Aponte, 2016).  
There is evidence of presynaptic norepinephrine action via the α1 receptor. 
Activation of the receptor triggers a decrease in the frequency of spontaneous GABA-
induced postsynaptic currents. This mechanism uses a phosphokinase-C signaling 
pathway, and is dependent on the activation of calcium and voltage gated potassium 
channels. Presynaptic activation of the α1 receptor was also noted to evoke glutamate 
release (Velásquez-Martínez et al., 2015). Both of these findings indicate that presynaptic 
adrenergic activation of the α1 receptor excites the dopaminergic neuron, and when 
glutamate and norepinephrine both interact with a single dopaminergic neuron, that 
neuron will fire longer bursts of action potentials (Mejias-Aponte, 2016).  
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Norepinephrine exposure quickly builds desensitization of the α1 receptor, so the 
excitatory effects are often short bursts and are less apparent when norepinephrine levels 
are tonically high, as in times of stress. This desensitization effect is apparently blocked 
by some stimulant drugs, notably cocaine and amphetamine (Broadley, 2010; Mejias-
Aponte, 2016). This represents yet another connection between the dopamine system and 
other behavioral pathways beyond PD, such as reward seeking behaviors and addiction 
(Friston et al., 2014; Mejias-Aponte, 2016; Velásquez-Martínez et al., 2015).  
The adrenergic system plays a role in regulation of dopamine levels. In studies 
where the locus coeruleus is lesioned, the tonic dopamine levels elsewhere in the brain 
were decreased. Agents known to inhibit the breakdown of norepinephrine and agonists 
of norepinephrine release were both found to correlate with higher dopamine levels in the 
midbrain. The structural similarity between the catecholamines allows for a degree of 
cross-talk between receptors and ligands. Norepinephrine is known to interact with the 
D2 and D4 receptors on dopaminergic neurons, albeit with lesser affinity than dopamine, 
which produces an inhibitory effect in neuronal activity (Mejias-Aponte, 2016). This 
effect is not surprising, as dopamine and norepinephrine differ by only one hydroxyl 
group in on the alpha carbon associated with the amine (Broadley, 2010). The adrenergic 
system therefore is an interesting route for future research to explore therapies aimed at 
increasing tonic dopamine levels in the midbrain.  
Mechanisms of Degradation 
It is a widely-accepted fact that the dopaminergic neurons in the ventral 
mesencephalon degrade in PD pathology, but the mechanism by which it occurs is not as 
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well established (DeMaagd & Philip, 2015; Vogt Weisenhorn et al., 2016). The numerous 
proposed mechanisms of neurotoxicity span many disciplines, however, this paper will 
focus on several molecular approaches. The protein α-synuclein is known to play a role in 
the pathology of many neurodegenerative diseases, and PD is no exception (Braak et al., 
2003). This protein aggregate is undoubtedly neurotoxic, but there are other factors 
involved in PD pathology which must also be considered. These include the high 
oxidative stress present in certain midbrain cells and the neurotoxicity implicit in 
dopamine’s biochemical pathways, and the deleterious effect of neuroinflammation 
(Graumann et al., 2002; Miyazaki & Asanuma, 2008).  
the Braak Hypothesis and α-synuclein  
Braak et al. (2003) proposed that neurodegeneration in PD is related to the spread 
of a pathogen, in a manner similar to a prion. They believe that sporadic PD, i.e. not the 
familial genetic variant, is caused by an unknown pathogen, which enters the body 
through the nasal cavity and is ingested, then absorbed in the gut and in the nasopharynx. 
The pathogen travels along the olfactory tract and enteric vagal nerve towards the central 
nervous system, as evident by the spread of α-synuclein aggregates which track the 
pathogen’s migration. The pattern of spreading both systemically and within the central 
nervous system is predictable and, as Braak et al. (2003) believe, contribute to a staging 
pattern which could ideally be used to quantitatively determine progression of PD. The 
spinal cord does not express α-synuclein aggregates until after the CNS is already 
involved, so the spinal cord therefore does not represent a potential route for this 
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pathogen to travel rostrally. This conception of PD is referred to as Braak’s hypothesis 
(Rietdijk et al., 2017).  
The involvement of the gut at an early stage of the disease is an astute observation 
on behalf of Braak et al. (2003). PD patients often report GI and olfactory symptoms 
before a diagnosis of PD is made, such as constipation, dysphagia, nausea, and anosmia. 
This data corresponds to findings of Lewy bodies in the GI tract and olfactory tract of PD 
patients (Rietdijk et al., 2017). Lewy bodies are neurofibrillary aggregates composed 
mostly of α-synuclein which are implicated in several neurodegenerative diseases, such 
as PD, Lewy Body Dementia, and parkinsonian multiple system atrophy (DeMaagd & 
Philip, 2015). There is a positive correlation between the level of Lewy body aggregates 
in the enteric nervous system and the severity of gastrointestinal symptoms (Braak et al., 
2003). PD is not diagnosed until motor symptoms are present, since the classic triad of 
motor symptoms is a key distinguishing feature of PD; this pre-diagnosis period is 
referred to as Incidental Lewy Body disease (Rietdijk et al., 2017).  
Within the gastrointestinal tract there are several differences between PD patients 
and controls. Disease-free control subjects had higher levels of certain microbiome flora 
compared to PD patients, notably in the abundance of prevotellaceae bacteria, whereas 
PD patients had significantly higher enterobacteriaceae. High level of enterobacteriaceae 
was associated with more severe postural instability and gait symptoms and less 
pronounced tremor, when compared within the PD patient subset. PD patients also 
exhibit greater intestinal permeability, a hallmark sign of intestinal inflammation. This is 
likely due to increased bacterial intrusions into the mucosal epithelia, oxidative stress, 
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and α-synuclein deposition. It is possible that the changes in gut flora predispose the 
patient to PD risk (Rietdijk et al., 2017).  
Patients’ diets could play a role in susceptibility. Fiber-rich diets promote growth 
of flora that produce short-chain fatty acids which mitigate inflammation, whereas diets 
high in fat and processed carbohydrates lead to a balance of gut flora that is more 
inflammation-prone (Rietdijk et al., 2017).  The link between diet and PD is not confined 
to bacteria. It appears that high-iron diets are also correlated with risk of PD due to the 
deleterious effects of storing metals in cells long-term (Hare et al., 2017; Tribl et al., 
2009).  
The spread of the pathogen suggested in the Braak hypothesis follows the vagus 
nerve. It originates in the enteric nervous system, then ascends the vagus until it reaches 
the dorsal motor nucleus of the vagus in the medulla, then enters the central nervous 
system. There it spreads to the brainstem, then the midbrain including the SN, and 
upward to the neocortex (Rietdijk et al., 2017). This hypothesis accounts for the general 
trajectory of α-synuclein pathology, but Rietdijk et al. (2017) point out that the α-
synuclein pathology spread is not all-encompassing. The structures listed are renowned 
for their susceptibility, but neighboring structures are virtually untouched. They use the 
example of the dorsal motor nucleus of the vagus, which exhibits Lewy body pathology, 
neighbors the solitary tract nucleus, which is spared. In animal models it has been shown 
that vagotomy is an effective measure to stop spread of α-synuclein to higher parts of the 
nervous system, but the practicality of this in humans is uncertain and should be 
considered on a case-by-case basis (Rietdijk et al., 2017).  
 39 
The neurons which are most susceptible to α-synuclein pathology have some 
features in common. They have a high baseline metabolic rate, which contributes to 
increased oxidative stress and α-synuclein misfolding. Additional factors are that they 
have high endogenous levels of α-synuclein and use monoamine neurotransmitters, their 
axons are long, branched, and have little to no myelination, and they are almost always 
constitutively active. It is possible that α-synuclein pathology travels from the peripheral 
to central nervous system along a path of least resistance, traversing up interconnected 
populations of highly susceptible neurons while the neighboring protected neurons are 
left untouched (Rietdijk et al., 2017).  
The protein α-synuclein’s neurotoxicity is similar to that of a prion. The natural 
state is a protein of unknown function which is ubiquitously expressed in the brain and 
some peripheral tissues. This form is not believed to be inherently neurotoxic. Pathogenic 
seed particles are then introduced, either sporadically via mutation or from ingestion as in 
the Braak hypothesis. Stuendl et al. (2016) found that the pathogenic particles are prone 
to oligomerization, and interact with natural state α-synuclein to coax it into the 
pathogenic form. Furthermore, the α-synuclein isolated from exosomes in the 
cerebrospinal fluid (CSF) was preferentially in a oligomerized state, and could convert 
nascent α-synuclein from other samples into the oligomer form (Rietdijk et al., 2017; 
Stuendl et al., 2016). Therefore it appears that the oligomers of α-synuclein are 
pathogenic, and in high numbers these aggregates form Lewy bodies. Oligomeric 
inclusions of α-synuclein in neurons interfere with cellular processes, and reduce network 
 40 
connectivity. In large enough quantities, this interference of the Lewy body with cellular 
function causes cellular stress unto death (Rietdijk et al., 2017). 
Unfortunately, the Braak hypothesis falls short of its goal to provide accurate 
staging for PD progression. In the subset of PD patients studied, between 51-83% follow 
the Braak staging patterns. About 7-11% do not express Lewy bodies in the dorsal motor 
nucleus of the vagus, while higher areas in the central nervous system are affected, a 
result incongruous with the staging hypothesis. 27-33% of PD patients had olfactory α-
synuclein aggregates, but none in the enteric nervous system, again contradicting the 
hypothesis which states that patients should have α-synuclein in both the olfactory and 
enteric pathways. These findings could be explained if α-synuclein pathology developed 
at multiple, sporadic locations. While the hypothesis is applicable to a majority of PD 
patients, it is not an all-inclusive diagnostic, but rather a guideline to be followed 
cautiously. Patients who were diagnosed with PD at a relatively young age, have a long 
disease course, and whose primary symptoms are motor, not dementia, align the closest 
with Braak’s hypothesis (Rietdijk et al., 2017).  
There is a further issue of timing of disease progression. Kordower (2013) found 
that most neurons in the SNc of PD patients have degraded within 4 years after diagnosis, 
and subsequent loss after this is incidental. Loss after 4 years could represent the loss of a 
compensatory mechanism or loss of non-dopaminergic neurons (Vogt Weisenhorn et al., 
2016), or it could be normal aging (Isaias et al., 2016; Kordower et al., 2013). Even in the 
earliest time points post-diagnosis, brains of PD patients examined post-mortem showed 
50-90% degradation in neurons expressing tyrosine hydroxylase, the catalyst of the rate 
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limiting step of dopamine synthesis, with subsequently marginal loss up to 4 years post 
diagnosis (Kordower et al., 2013). Braak’s hypothesis does not mention timing of α-
synuclein spread, so it is hard to tell if α-synuclein invades the SNc while it is healthy 
and causes degeneration, or it the Lewy body pathology only infringes upon the SNc 
once the neurons have already degenerated due to other means (Rietdijk et al., 2017; 
Stuendl et al., 2016).  
Oxidative Stress 
Another mechanism of cellular toxicity which has garnered much attention is that 
of oxidative stress. SNc neurons are densely packed with mitochondria, and have 3-fold 
greater respiratory energy demands than VTA cells at baseline (Vogt Weisenhorn et al., 
2016).  This high metabolic rate generates a similarly high degree of reactive oxygen 
species (ROS), reactive nitrogen species (RNS), and is conducive to the auto-oxidation of 
dopamine (Miyazaki & Asanuma, 2008). Altogether, these byproducts of oxidative 
respiration in cellular metabolism cause inflammation and pose serious threats to the 
integrity of the cells which contain them (Crotty et al., 2017).  
The brain is predisposed to oxidative stress. The brain accounts for 2% of the 
body’s weight, yet its metabolic rate consumes about 20% of the body’s total oxygen 
supply and a significant portion of that oxygen is converted into ROS (Crotty et al., 
2017). A significant portion of the oxidative stress in the ventral mesencephalon is due to 
dopamine. Under normal conditions, dopamine levels are regulated and the 
neurotransmitter is packaged in vesicles, but extravesicular dopamine in high 
concentration is able to react in many different ways (Miyazaki & Asanuma, 2008).    
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Therapy with L-DOPA is the most common treatment for PD, but long term 
treatment can have deleterious effects. L-DOPA therapy introduces high levels of 
exogenous dopamine in cells which reacts in ways that generate ROS and RNS. In 
advanced PD, the SNc is degraded to a point where so few dopaminergic neurons remain 
that L-DOPA is unable to elicit an appreciable effect. In both of these cases there is a 
surplus of dopamine in the microenvironment which cells process in a variety of ways 
that pose a risk in terms of oxidative stress (Miyazaki & Asanuma, 2008). 
Some ROS result from the normal degradation pathway of dopamine. The enzyme 
MAO converts dopamine into dihydroxyphenylacetic acid (DOPAC) and produces H2O2 
as a byproduct. The H2O2 in dopaminergic neurons has been shown to interact with 
metals, producing the hydroxide (OH-) ion. The hydroxide ion is very reactive and 
constitutes a major risk to cellular processes. Iron has the apparent highest affinity for 
interaction with hydrogen peroxide (Miyazaki & Asanuma, 2008). This finding is 
interesting, because iron-rich diets early in life are a risk factor for developing PD 
pathology later in life (Hare et al., 2017).   
The quinones and free radicals which result from non-enzymatic auto-oxidation of 
dopamine are implicated in neurotoxicity. In an oxidative environment, dopamine 
spontaneously oxidizes, generating quinones and superoxide ions, O2
1-. The enzyme 
superoxide dismutase converts O2
1- into hydrogen peroxide, which is less cytotoxic but 
still harmful to cells, as described above. Superoxide ions also interact with nitric oxide 
radicals, NO-, yielding the RNS species peroxynitrite (ONOO-). Free radicals, ROS, and 
RNS species are highly cytotoxic. They disrupt protein structure, cause stress to cells, and 
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result in inflammation (Crotty et al., 2017; Miyazaki & Asanuma, 2008). Whereas ROS 
and RNS exercise a harmful effect on the neuron in which they are made as well as 
neighboring cells in the local environment, the deleterious effects of quinones are often 
limited to the neuron which produced them (Fedorow et al., 2005; Graumann et al., 2002; 
Miyazaki & Asanuma, 2008). 
Structurally, quinones formed from catecholamines have ketone groups where the 
hydroxyl groups were in the catechol form (Pubchem, n.d.). The quinones produced in 
the auto-oxidation of dopamine have a wide range of cellular effects. Miyazaki and 
Asanuma (2008) find that dopamine quinones are also generated from dopamine 
oxidation by enzymes with cyclooxygenase activity, such as prostaglandin H synthase, 
lipoxygenase, tyrosinase, and xanthine oxidase. L-DOPA is also oxidized to a quinone 
form without being converted to dopamine first, and its consequences are similar to the 
observed effects of its dopamine counterpart (Miyazaki & Asanuma, 2008). 
Dopamine quinone reacts covalently with cysteine. The cysteine residue is often 
found in the active site of proteins, so covalently binding dopamine effectively inhibits 
protein function (LaVoie & Hastings, 1999; Sulzer & Zecca, 2000). Glutathione, an 
enzyme known for alleviating oxidative stress, has a prominent cysteine residue which is 
targeted by dopamine quinones. This exacerbates the toxicity of quinones and stresses 
associated with a highly-oxidizing environment by degrading this essential 
neuroprotective antioxidant (LaVoie & Hastings, 1999).  
The oxidative stress caused by dopamine metabolite have several key implications 
in the midbrain dopaminergic system. Dopamine quinones interact with cysteine residues 
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in tyrosine hydroxylase and render it inactive (Miyazaki & Asanuma, 2008). This enzyme 
catalyzes the rate-limiting step of dopamine synthesis (Broadley, 2010), thus inactivation 
of the enzyme may lead to lower dopamine levels. Dopamine quinone has also been 
found to bind with cysteine residues in the dopamine transporter DAT, preventing 
dopamine uptake at the synapses (Miyazaki & Asanuma, 2008). The dopamine quinones 
have an important action regarding the protein product of one of the few PD-associated 
mutant genes, the parkin protein, causing it to be less soluble and inactivating its 
ubiquitin ligase function (LaVoie & Hastings, 1999; Sulzer & Zecca, 2000). This has 
been linked to apoptotic degenerations in dopaminergic neurons, and mutant parkin 
expression is positively correlated with presence of aminochrome (Crotty et al., 2017). 
Furthermore, dopamine quinones have been shown to conjugate with α-synuclein. This 
promotes aggregation of the insoluble, pathogenic form of the protein, and contributes 
greatly to the formation of Lewy bodies. By decreasing solubility of α-synuclein, the 
catecholamine-derived quinones promote the destruction of synaptic vesicular 
membranes (Miyazaki & Asanuma, 2008). 
Dopamine and L-DOPA quinones are a key component to the formation of 
neuromelanin. The quinones are further oxidized to cyclized aminochromes, either 
enzymatically or because of the oxidative environment. Dopaminochrome and L-DOPA-
chrome both polymerize, and are a major component of the pigmented neuromelanin 
aggregates in neurons (Miyazaki & Asanuma, 2008). Interestingly, neuromelanin is 
found in only two of the three cell catecholaminergic types in the brain: dopaminergic 
and noradrenergic cells express neuromelanin, while adrenergic ones do not. 
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Neuromelanin is not expressed in non-catecholaminergic cell types (Fedorow et al., 
2005).   
Fedorow et al. (2005) also observe that whereas the dopaminergic and 
noradrenergic neurons are capable of expressing neuromelanin, not all cells in these 
lineages do in fact express it, so neuromelanin expression cannot be used as an exact 
quantification of neurodegeneration. Even so, the brains of PD patients when examined 
post-mortem are uniformly lacking in pigmentation (Kordower et al., 2013; Vogt 
Weisenhorn et al., 2016). Research has also shown that the highest concentration of 
neuromelanin in the brain is in the dopaminergic neurons of the ventral mesencephalon, 
in particular the SN (Fedorow et al., 2005).  
It is believed that neuromelanin has a neuroprotective function in the cell. An 
inverse relationship was established between neuromelanin expression and vulnerability 
in PD pathology (Hirsch et al., 1988). This may be due to the tendency of neuromelanin 
to aggregate the harmful metabolites of dopamine and neutralize their oxidant behavior 
(Fedorow et al., 2005; Miyazaki & Asanuma, 2008; Sulzer & Zecca, 2000). Accordingly, 
an investigation of cells that MRI images showed to be high in neuromelanin were found 
to have similarly high amounts of binding to the dopamine D2 receptor, confirmed by 
PET scan (Ito et al., 2017).  
Neuromelanin plays a role in neutralizing potentially toxic metal cations. Iron, 
zinc, lead, copper, manganese, cobalt, mercury, and other metals can damage cells in 
high concentrations, especially in the oxidative environment within the cell. In particular, 
iron has become an area of interest for PD research. There is evidence linking iron 
 46 
accumulation in the SN to PD disease progression. Neuromelanin-expressing cells seem 
to resist metal cation damage more robustly compared to cells without pigment (Fedorow 
et al., 2005; Tribl et al., 2009).  
Neuromelanin comprises one aspect of the cellular neuroprotection from 
oxidative stress, and it is attractive to PD researchers because of its direct involvement in 
the metabolism of dopamine. Other neuroprotective systems exist within the cell, albeit 
not as intricately tied to dopamine metabolism. One such system involves purine 
metabolism (Crotty et al., 2017). It would be worthwhile to explore the connections 
between the multitudinous systems of protection available to the dopaminergic neuron in 
future research.  
Towards Early Detection 
As there is not yet any cure for PD, it is imperative to detect the disease early. 
Dopaminergic neurons are lost exponentially more rapidly in the early part of disease 
progression than in the advanced stages (Kordower et al., 2013), so treatments initiated 
earlier will likely be able to protect many more neurons and preserve brain function for a 
longer period (Breen & Lang, 2017; DeMaagd & Philip, 2015). Towards this goal, there 
is a wealth of research examining the possibilities of PD-linked biomarkers and signals in 
imaging of PD brains.  
Breen and Lang (2017) highlight that the cognitive and motor symptoms of PD 
appear far earlier than the diagnosis is made. There is a trend among clinicians to observe 
symptoms and monitor their progression post-onset until they conclusively confirm or 
rule out PD, referred to as the ‘wait and watch’ approach. Given the early onset of 
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symptoms, it would be worthwhile to develop a measure to detect PD earlier in the 
prodromal stage (Breen & Lang, 2017).  
Darweesh and colleagues (2016) found some surprising results about the time 
frame of prodromal PD. On cognitive tests, PD patients began to show significantly 
greater decline in performance compared with control subjects about seven years prior to 
PD diagnosis. This correlated with data showing that patients reported having difficulty 
with complex tasks involving motor and non-motor function, especially traveling, about 
seven years pre-diagnosis. Patients reported that their motor symptoms first began to 
interfere with daily life about five years before a diagnosis was made, particularly with 
regard to eating, and the gastrointestinal dysregulation and tremor noted in PD could be 
detected up to ten years prior to diagnosis. Motor impairments onset in the upper limbs, 
generally as finger tapping or arm swinging, and then progress into tremor about five 
years prior to diagnosis (Darweesh et al., 2016). Considering these factors and more, 
guidelines for the diagnosis of prodromal PD were published recently. The study applied 
their guidelines to existing data of patient cohorts and the assessment was shown to be 
95% accurate in discerning prodromal PD. However, the guidelines have not yet been 
assessed for predictive accuracy in the general population (Mahlknecht et al., 2016).  
PD presents in familial and idiopathic varieties. The vast majority of PD cases are 
idiopathic, but the familial connection indicates a genetic component to PD exists as well. 
Several genetic mutations have been found in conjunction with PD. These include 
mutations inherent in the genes encoding α-synuclein (SNCA), parkin (PRKN2) and 
superoxide dismutase-2 (SOD2), as well as other genes not covered in this paper 
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(DeMaagd & Philip, 2015; Miyazaki & Asanuma, 2008). These genetic mutations are 
salient markers of neurogenerative potential, but do not account for the pattern of 
degeneration observed in PD. Poulin et al. (2014) identified 96 genes that are potentially 
implicated in PD pathology regarding the selective vulnerability of SNc dopaminergic 
neurons. It is not yet clear which of these genes are responsible for familial PD 
(DeMaagd & Philip, 2015). While the genes mentioned here are shown to be involved in 
the pathology of PD, having a mutation in one gene does not guarantee that an individual 
will develop the disease (Mantero et al., 2017). Similarly, the ethics of genetic testing are 
often debated due to generalizability of data from specific patient populations, the 
predictive value of the results, and the financial cost of the test (DeMaagd & Philip, 
2015). For these reasons, genetic testing cannot stand alone as a definitive diagnostic of 
PD.  
Neuroimaging provides useful insight to the diagnosis and progression of PD. 
Magnetic resonance imaging (MRI) is a readily available, effective, and non-invasive 
technique for imaging the brain in vivo. Studies have found that the substantia nigra can 
be visualized by MRI, and have attempted to quantify its appearance on high (3T) and 
ultra-high (7T) field strength iron-sensitive MRI (Schwarz et al., 2014). The ventrolateral 
extensions of the SNc into the SNr, i.e. nigrosomes, are the most susceptible cell 
populations in PD pathology (Gibb & Lees, 1991). Nigrosome-1, located in the posterior 
third of the SN, was found to have a characteristic ‘swallow-tail’ shape in healthy study 
subjects. The swallow tail sign appears as a dark wedge on the 3T high field strength 
MRI constructed image. Researchers concluded that the presence of the swallow tail sign 
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on the 3T MRI was clearly indicative of the non-PD state, whereas absence of the 
swallow tail was associated with the PD state but was not conclusive. The swallow-tail 
could be absent due to factors, such as high iron content in the surrounding SN cells, that 
were not inherently indicative of PD (Schwarz et al., 2014).  
Mahlknecht and colleagues (2017) emphasized the utility of high and ultra-high 
field strength MRI in their analysis of MRI techniques’ accuracy at detecting PD. An 
MRI at regular field strength of a PD brain and that of a healthy brain appear the same for 
clinical purposes. Differences are only apparent at the high and ultra-high strength levels, 
as alluded to in the description of the swallow tail sign (Schwarz et al., 2014). The SNc of 
healthy patients is generally hypo-intense, with an ovoid shaped hyper-intensity along the 
dorsolateral border. This hyperintensity, called the dorsolateral nigral hyperintensity 
(DNH), is believed to correspond to nigrosome-1 based on correlation with a 7T post-
mortem MRI study. The absence of DNH at least unilaterally in in vivo 3T MRI and a 
bilateral absence in an in vivo 7T image were found to be significant markers of PD 
pathology. Furthermore, the DNH was not absent in movement disorders that exhibit 
parkinsonism but do not follow the same pathology as PD. Absence of the DNH can 
potentially be a key diagnostic feature in the future (Mahlknecht et al., 2017).  
There is a large body of research exploring the link between iron accumulation in 
the SN and PD pathology. One study purportedly established a correlation between iron-
fortified diets early in life and developing PD later. Iron accumulates in the brain 
throughout life, and is mostly stored in glia, although some iron is stored in neurons. 
These pools continue to grow with age, until they are eventually overwhelmed. At this 
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point iron is released into the cytoplasm of neurons, where it interacts with dopamine and 
forms cytotoxic metabolites (Hare et al., 2017). This is corroborated in that higher than 
average iron levels are noted in the SNc in PD patient’s brains (Tribl et al., 2009). Hare et 
al. (2017) found that incidence of PD after the age of 50 is higher in nations that adopted 
iron-fortification in dietary staples than in nations that have not mandated iron 
fortification. Additionally, incidence increased after these policies were implemented. It 
would be interesting to continue this line of research to determine any diagnostic 
significance of dietary iron intake, both in early life and during the disease (Hare et al., 
2017).  
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DISCUSSION 
 Parkinson’s Disease is a complex and multifaceted neurodegenerative disorder of 
dopamine in the midbrain, although many more systems and structures are involved 
beyond the basal ganglia. The ventral mesencephalon is perhaps best considered as the 
crux of the Parkinsonian model where all the diverse underlying processes converge, 
giving rise to the set of symptoms we recognize as Parkinson’s Disease. Dopamine 
deficiency is the easily identifiable factor for causing the disease, but the mechanisms 
which cause reduced dopamine levels are numerous. It is impossible to say at this point if 
any single mechanism of degeneration is the quintessential ‘parkinsonian’ mechanism, 
since neuronal degeneration results from such a range of insults. What is likely, as 
alluded to by Poulin et al. (2014), is that PD arises from a multiple-hit model. Towards 
this end, it could be helpful to consider PD from a holistic perspective, as a dysregulation 
in the homeostatic interactions of multiple neurological systems.   
 Much research has been dedicated to explaining the selective susceptibility of 
neurons in the SNc. Vogt Weisenhorn et al (2016) provide an excellent account of the 
macro and micro-organization of the dopaminergic neurons in the ventral 
mesencephalon. The main macroscopic pathologic consequence in the ventral 
mesencephalon is the loss of the neurons that project from the SNc, primarily from the 
ventrolateral tier of the SNc to the striatum (Vogt Weisenhorn et al., 2016). This 
connection is not part of the three pathways commonly used to model connections in the 
BG circuit. Most models assume cortical inputs flow through the striatum or STN, then 
on to the Gpi or SNr. The nigrostriatal connection runs opposite the flow of information 
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in the direct or indirect pathway, likely as a feedback modulator (Yetnikoff et al., 2014). 
When dopamine is not present striatal activity increases pathologically. The resulting 
synchronization in BG circuits (Weinberger & Dostrovsky, 2011) is perhaps similar to a 
feedback between microphone and a speaker, where small input waves grow into chaotic 
output waves due to lack of dampening, although the physics of the BG and audio 
circuitry are admittedly vastly different. The conceptual BG circuit operates well with the 
view that dopamine is predominantly an inhibitory neurotransmitter within the BG. Still, 
the question of why the ventrolateral tier of the SNc degrades is not addressed. 
 The fact that multiple researchers have all found distinctions within the 
organization and biochemistry of the midbrain dopaminergic neurons indicates that 
heterogeneity within the region exists and is important to its function. From Dahlström 
and Fuxe (1964) until present, researchers continue to find spatial and molecular 
delineations within the midbrain. The cell groups A8-A10 align consistently with 
neuroanatomical structures, thus confirming that the organization of the brain follows 
both spatial and functional divisions. Since then, research has found overwhelming 
evidence for the differences and distinctions between the cell types, yet none of the 
characteristics can entirely explain the selective pathology observed in PD (Anderegg et 
al., 2015; Brichta & Greengard, 2014; Vogt Weisenhorn et al., 2016). 
 It seems that much of the literature is converging on the toxicity of oxidative 
stress as a major mechanism of cell death in PD. In this mechanism, oxidative stressors 
within the cell cause damage and death, which results in neuroinflammation that in turn 
causes more stress to cells (Crotty et al., 2017; Graumann et al., 2002). The susceptible 
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neurons in the SNc are characterized by a high baseline level of metabolic activity, with a 
resting metabolic state 3x more active than the neighboring VTA dopaminergic 
population (Vogt Weisenhorn et al., 2016). Discerning the cause or necessity of this high-
energy state could be useful for early-stage therapies, before significant degeneration 
occurs.  
 The susceptibility of the small subset of dopaminergic neurons in the SNc could 
be explained by oxidative stressors overloading the compensatory mechanisms. Perhaps, 
in the VTA or other cell populations with more regular baseline metabolism, a surge in 
toxic oxidants could be quenched entirely by cellular mechanisms. There may be ample 
ALDH1a1 to enzymatically metabolize dopamine, dopamine levels could be kept in 
check before pathological amounts of quinones accrued, and neuromelanin would be able 
to handle the rest. In such a system, the cellular antioxidants, e.g. glutathione, would be 
able to handle the shock of an increased oxidative load (LaVoie & Hastings, 1999; 
Miyazaki & Asanuma, 2008; Sulzer & Zecca, 2000).  
On the contrary, the SNc cells are already likely close to their capacity to handle 
oxidative loads. Larger quantities of oxidants build up over time, and a surge in the 
respiratory demands could theoretically push a cell past its threshold for repair. For 
example, glutathione is involved in a plethora of essential biochemical processes such as 
DNA repair and iron metabolism (Tribl et al., 2009). If high levels of glutathione have 
been covalently bonded to dopamine quinones, then the cell will experience damage from 
i) free radicals that glutathione cannot neutralize, and ii) the inability to perform 
necessary reactions to maintain cellular function and life (Crotty et al., 2017; Miyazaki & 
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Asanuma, 2008). There is also evidence to show that iron and other cations accumulate in 
the cells, further exacerbating cellular damage (Miyazaki & Asanuma, 2008; Tribl et al., 
2009). 
As cells in the SNc are predisposed to oxidative shock due to dense mitochondria 
in unmyelinated axons, and have high levels of potentially cytotoxic catecholamines 
(Rietdijk et al., 2017), it seems highly likely that the effects of oxidative stress are more 
prevalent in this population as compared to others. The account of molecular 
heterogeneity in dopaminergic subpopulations of the ventral mesencephalon confirm that 
the DA1A subgroup lacked transcription factors conferring neuroprotection (Anderegg et 
al., 2015; Poulin et al., 2014; Vogt Weisenhorn et al., 2016), thus the molecular biology 
aligns well with the oxidative stress model. It would be fruitful if future research could 
continue to quantify this line of reasoning empirically. 
Currently L-DOPA is the best therapy for treating PD, but it has some drawbacks 
(DeMaagd & Philip, 2015). As noted in Crotty et al. (2017) and others, increased levels 
of dopamine metabolites can have deleterious effects in a cell. Likewise, in the long term, 
L-DOPA therapy has been linked to dystonia and other neurological imbalances. For this 
reason, L-DOPA is often administered in conjunction with neuroprotective agents 
(DeMaagd & Philip, 2015).  
An effective route for therapy is to block the α2 adrenoceptor. This results in 
lower extracellular dopamine metabolites, which reduces the toxic threat to local neurons 
(Mejias-Aponte, 2016). There is a close interaction between the dopamine system and the 
adrenergic system, which opens up the adrenergic system as an organic tool by which to 
 55 
control dopamine levels. Ideally, if the dopamine levels can be artificially controlled 
early in disease progression, then there is a possibility of delaying neuronal death. It is 
unfortunate that current treatment is only able to manage symptoms, and cannot yet slow 
disease progression (Breen & Lang, 2017).  
The adrenergic system is also a potential candidate for the origin of neurotoxicity. 
In rodents, low levels of norepinephrine were associated with a low dopamine level, and 
induced parkinsonism. This effect was reversed by administering dopamine (Mejias-
Aponte, 2016). If a lesion or imbalance occurred somewhere in the adrenergic system 
that led to decreased norepinephrine it would lower ambient dopamine levels, as in the 
rats. Likewise, it would be interesting to explore if an increase in norepinephrine levels 
could raise dopamine concentration to pathological levels and cause degeneration by 
oxidative stress, thus showing another possible origin of degeneration.  
The protein α-synuclein is responsible for a portion of the pathology in PD as 
well. It has been implicated in Lewy body pathology and is indisputably an agent of 
degeneration in PD, Alzheimer’s Disease, Huntington’s Disease, and many other 
neurodegenerative diseases (DeMaagd & Philip, 2015; Vogt Weisenhorn et al., 2016). 
Braak et al. (2003) treats α-synuclein as a prionic pathogen which enters the body in the 
nasal cavity and gut, then travels to the central nervous system along the vagus nerve. 
This system has been shown to reflect a majority of PD cases’ progression, but it is not 
always accurate. The α-synuclein protein has reliably been shown to act as a prion by 
corrupting non-pathological α-synuclein proteins in a cell (Stuendl et al., 2016), and α-
synuclein has been linked to cellular degradation (Vogt Weisenhorn et al., 2016). 
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However, the progression of α-synuclein pathology through the body, as measured by 
Lewy body deposition, does not always match the hypothesis of Braak et al. (2003) 
(Rietdijk et al., 2017). More studies are needed to determine the mechanism responsible 
for α-synuclein deposition that breaks from Braak’s hypothesis.  
Highly oxidative environments influence α-synuclein biology, favoring 
conversion of soluble α-synuclein to insoluble fibrils that oligomerize and aggregate. 
These aggregates form the Lewy bodies which are characteristic of the degeneration seen 
in PD and other neurodegenerative diseases (Crotty et al., 2017; Miyazaki & Asanuma, 
2008). As noted, SNc dopaminergic neurons are highly susceptible to oxidative stress, 
and are therefore susceptible to α-synuclein induced degradation as well. This is another 
finding which gives insight as to why the SNc is especially vulnerable to degeneration.  
Despite the efficiency of the oxidative stress model in explaining 
neurodegeneration in the SNc, there are still many inconsistencies. Degradation in the 
SNc does not progress at a uniform pace. PD is generally diagnosed when about 60% of 
dopaminergic neurons in the SNc have degraded (Vogt Weisenhorn et al., 2016). 
Kordower et al. (2013) found that at the earliest points post-diagnosis, 50-90% of the SNc 
dopaminergic neurons were degraded, and loss was virtually complete 4 years post-
diagnosis. Worsening of symptoms after this point is likely due to loss of compensatory 
mechanisms. There is a large amount of research dedicated to ascertaining what causes 
that sudden and rapid decline in SNc neurons (Vogt Weisenhorn et al., 2016).  
In terms of the multiple-hit hypothesis, it is possible that there is a balance of 
many symptoms maintaining the equilibrium of the BG, and several systems must be 
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damaged at once for pathogenesis to occur. High oxidative load is an attractive 
explanation for the pathology of PD, but it is essential to remember that the majority of 
the population does not develop PD in their lifetime. Incidence is around 1% of elderly 
adults in developed nations (Breen & Lang, 2017; Brichta & Greengard, 2014; DeMaagd 
& Philip, 2015; Vogt Weisenhorn et al., 2016). Even PD patients go many years without 
significant degeneration, before they develop symptoms. It is evident that high oxidative 
stress cannot alone be responsible for the PD pattern of neurodegeneration, otherwise all 
people would be prone to develop PD. Therefore is it possible that PD results from 
multiple mutations arising in critical genes within the systems that mitigate oxidative 
load, rendering the predisposed SNc cells more susceptible to oxidative stress, 
neuroinflammation, and neurodegeneration. A multiple-hit hypothesis as the etiology of 
PD accounts for the molecular and macroscopic pathology which gives rise to PD.  
Since neurodegeneration occurs rapidly and early in disease progression, it would 
be helpful in terms of therapies to initiate treatment early. If a therapy could be developed 
to slow progression of the disease, it would be enormously beneficial to initiate treatment 
when SNc neurons are still alive. Even in current therapies, patients’ quality of life 
benefits from early treatment (DeMaagd & Philip, 2015). Several potentially diagnostic 
markers have been identified on high power MRI images (Mahlknecht et al., 2017; 
Schwarz et al., 2014). Theoretically, if a patient has a history which aligns with criteria 
for prodromal diagnosis as per Mahlknecht et al. (2017), then they could receive routine 
diagnostic scans. This would ideally identify PD patients much earlier than the current 
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techniques, and maximize the result of therapies. There is a bright future for PD 
treatment, beginning with the diagnostics reviewed here.  
 
CONCLUSION 
 PD is a complex neurodegenerative disease related to irregularities in dopamine 
biology in the ventral mesencephalon. Its formal study date back to the early 19th century 
when Dr. James Parkinson first described the motor symptoms we now know as 
parkinsonism. These motor symptoms are due to the depletion of dopaminergic neurons 
in the SN, which causes irregularities in neuronal firing patterns within the BG. Patients 
exhibiting the pathological firing patterns are unable to integrate smooth motion, and 
have significant cognitive deficits in tasks involving cortical executive function.  
 The degeneration of the SNc in PD pathology is complex, and tied to many brain 
systems. Dopaminergic neurons in the SNc degrade preferentially compared to 
neighboring dopaminergic populations in the VTA. It is proposed that this is due to 
higher baseline oxidative stress in the SNc, pathologic aggregation of α-synuclein, iron 
accumulation, and a variety of other factors. The dopaminergic system’s interaction with 
other neurotransmitter systems opens the possibility of controlling dopamine levels by 
means other than exogenous L-DOPA, and are potential areas for future treatments.  
Recent advances in neuroimaging present new opportunities for early detection of 
PD. Early detection of PD is essential to slowing disease progression, because more than 
50% of the neurons in the SNc have degraded by the time clinicians make a diagnosis in 
the current system. L-DOPA therapy is the best therapy currently available. However, it 
is ultimately cytotoxic, so earlier treatment of the underlying cause of degeneration could 
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be more beneficial to the patients’ quality of life as the disease progresses. Future 
research should focus on determining the reason that the SNc is especially susceptible, 
and determining the multi-hit mechanism of neurodegeneration. Clinicians and research 
currently focuses on maintaining patients’ quality of life and management of symptoms 
as we progress towards the ultimate goal, a cure for PD.  
Future Research 
There is still a lot left to learn about PD. On a molecular level, it would be helpful 
to learn more about the differential expression of genes that play a role in conferring 
protection or susceptibility in the ventral mesencephalon dopaminergic complex. There is 
still no definitive consensus as to why the ventrolateral tier of the SNc degrades more 
than elsewhere in the SNc, and why the SNc is more susceptible than other dopaminergic 
neurons. It would also be interesting to explore the role of epigenetics in expression of 
the genes involved in these pathways, such as differential expression of transcription 
factors, and the differences in post-translational modifications of gene products in the 
SNc and VTA. Ideally, some of these differences could be diagnostically significant of 
PD and act as biomarkers to aid early diagnosis (Poulin et al., 2014).  
The adrenergic system has a profound interaction with the dopaminergic system. 
Future research would be well spent to flesh out the details of this interface more 
completely. The adrenergic system offers an organic interface to manipulate dopamine 
levels in-vivo, without using exogenous dopamine metabolites that are known to be 
cytotoxic. Of course, a treatment such as this would need to be implemented early on in 
disease progression, so that there is still a significant quantity of dopaminergic neurons 
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extant in the SN when therapy is initiated. It is worth exploring the ability of the 
adrenergic inputs to the dopamine system to raise dopamine levels, since a lesion in the 
brain that increases norepinephrine expression could endogenously raise dopamine to 
pathological levels. There is also a limited affinity of norepinephrine for the dopamine 
receptors D2 and D4, so in the absence of dopamine it might be worthwhile to explore a 
possible compensatory role for norepinephrine (Mejias-Aponte, 2016).  
Oxidative stress as a mechanism of degeneration is an area of ongoing research. 
Specifically, the fate of neuromelanin is not known. It is believed to confer 
neuroprotection on cells, but in the SNc it disappears. The disappearance of neuromelanin 
precedes cell death, as non-pigmented cells in the SNc of PD brains still express the 
tyrosine hydroxylase enzyme which regulates dopamine synthesis. It is also yet uncertain 
why neuromelanin is found in catecholaminergic cells containing dopamine and 
norepinephrine, but not in cells with epinephrine. Epinephrine is the only substitute 
amine out of the three, so it would be interesting to explore if secondary amines are 
unable to polymerize as primary amines can, and if this has any implications in the 
pathology of PD. Understanding the biology of neuromelanin and its metabolism could 
give insight as to a possible cure for oxidative stress-induced degeneration (Fedorow et 
al., 2005). 
Mahlknecht et al. (2017) found that the absence of DNH was indicative of PD. 
Mahlknecht (2016) described symptoms to look for in patients who have not been 
diagnosed with PD, in order to diagnose them earlier, i.e. before the SN degrades so 
thoroughly. It would be helpful to combine the findings and create a statistical measure 
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that can assess a patient’s symptoms and imaging results, and calculate an empirical 
diagnosis of PD. Of course, any such calculation would need to be verified by a clinician, 
but it could be very helpful especially in early diagnoses.  
Researching the brain is complex. It is helpful to have models of brain function 
that can be used to manipulate the systems and structures that compose the brain, without 
inflicting invasive procedures on patients in the name of science. However, current 
technology is limited by processing power that falls far short of encompassing the 
intricacies of the brain. Technology clearly lags behind biology in this regard. 
Computational biologists would be wise to develop a model of the brain, or at least small 
parts of it, that can be manipulated. A tool like this would be quintessential in PD 
research (Helie et al., 2013). 
PD is similar to several other degenerative diseases. More research is needed to 
discern the cause of PD, ALS, Alzheimer’s Disease, and Lewy Body Dementia. Some 
researchers propose that these diseases share a common origin, and our classification of 
the disease depends on the pattern by which it spreads rather than by the underlying 
mechanism of the disease itself (Recabarren & Alarcón, 2017). A theory such as this, if 
proven true, would have unprecedented benefit for research of neurodegenerative 
diseases as a whole, and could drastically improve the way we conceptualize these 
diseases.  
A final point of curiosity concerns the BG and their connections to nuclei not 
involved in PD pathology. The BG are connected to the limbic system via the ventral 
striatum, and they are implicated in many complex behaviors involving learning, and 
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reward pathways, such as addiction. It would be interesting to see if and how these 
behaviors change in a PD patient. This would give further insight into the nature of the 
connections of the BG and its role in cognition.  
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